Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Bausch + Lomb Corporation ( (BLCO) ).
Bausch + Lomb has received U.S. FDA 510(k) clearance for its new Bi-Blade+ dual-port vitrectomy cutter and an Adaptive Fluidics software update for the Stellaris Elite Vision Enhancement System. The Bi-Blade+ device boosts cutting speed to 25,000 cuts per minute, delivers about 25% higher vitreous flow versus the prior Bi-Blade model, and reduces cutter vibration to enhance surgeon comfort and control.
When paired with Adaptive Fluidics, the system automatically adjusts fluid infusion based on real-time vacuum levels, improving intraocular pressure stability and reducing average infusion pressure during vitrectomy procedures. The combined technologies are intended to make retinal surgery more efficient and predictable, potentially strengthening Bausch + Lomb’s position in the retinal surgery equipment market and offering clinicians tools to support more consistent patient outcomes.
The most recent analyst rating on (BLCO) stock is a Hold with a $16.34 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is most constrained by weak financial performance—multi-year net losses and negative free cash flow—despite solid revenue growth and a supportive balance sheet in the latest period. Offsetting this, the earnings call was strong with clear 2026 guidance for improved margins and EBITDA growth, and the technical setup is constructive with the stock trending above key moving averages. Valuation is held back by negative earnings and no stated dividend support.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company that develops and markets contact lenses, prescription eye medicines, over-the-counter eye care products, and surgical devices. With a long-standing focus on innovation in ophthalmology, the company targets both vision correction and surgical markets, aiming to improve standards of care for patients worldwide.
Average Trading Volume: 418,534
Technical Sentiment Signal: Buy
Current Market Cap: $5.64B
For detailed information about BLCO stock, go to TipRanks’ Stock Analysis page.
